AVEO Oncology

AVEO Oncology, an LG Chem company, wishes everyone a happy and safe #4thofJuly.

Mike Ferraresso, Chief Commercial Officer, AVEO Oncology, an LG Chem company, recently shared valuable insights and the latest trends in customer engagement as a panelist at the Axtria - Ingenious Insights Ignite 2024 Conference. The seminar, entitled “The Evolution of the Customer Engagement Models to Achieve Greater Customer Centricity,” explored how the life sciences industry can best serve customers in times of challenging access and unique local market dynamics. #AxtriaIGNITE #Pharma #Lifsciences #Leadership #oncology #biotech

AVEO Oncology, an LG Chem company, joins the International Kidney Cancer Coalition (IKCC) for #WorldKidneyCancerDay  2024 today, June 20th, to call attention to the 431,000 people worldwide diagnosed with #kidneycancer every day, and applauds IKCC in its mission to empower the kidney cancer community through advocacy, awareness, information, and research. 

Today we commemorate #Juneteenth and the emancipation of enslaved African Americans. Join us in learning, engaging, and supporting initiatives that promote racial justice and equality. AVEO Oncology, an LG Chem company, is committed to a diverse, inclusive, and equitable future.

AVEO Oncology, an LG Chem company, honors the FDA Oncology Center of Excellence National Black Family Cancer Awareness week June 13th through June 19th. During this time, we acknowledge the challenges faced by black families affected by cancer and share our support by raising awareness. #oncology #pharma #biotech #blackfamcan

LG Chem and AVEO Oncology, an LG Chem company, announced today that it has enrolled the first patient in the United States for a Phase 1 clinical study of LB-LR1109, LG Chem’s first proprietary anti-cancer investigational drug candidate, a next-generation immune checkpoint inhibitor. LG Chem will be collaborating closely with AVEO, a wholly owned subsidiary of LG Chem, that specializes in oncology development and commercialization. The study is a Phase 1, multi-center, open-label, non-randomized, dose escalation study designed to determine the recommended Phase 2 dose of LB-LR1109, and to evaluate the safety and tolerability of the investigational drug in participants with advanced or metastatic solid tumors. Learn more here: https://lnkd.in/eyPi2B4k

This June, AVEO Oncology, an LG Chem company, honors the 37th annual #NationalCancerSurvivorsDay (June 2nd) as well as the American Association for Cancer Research’s  #NationalCancerSurvivorMonth. During this time, we would like to recognize all cancer patients, as AVEO remains focused and committed to providing innovative solutions to improve their lives.

This #MemorialDay and throughout the year, AVEO Oncology, an LG Chem company, remembers and honors the brave U.S. military men and women who made the ultimate sacrifice to protect our country and freedoms.

Michael Bailey, President & CEO of AVEO Oncology, an LG Chem company, recently shared his extensive knowledge and years of industry experience with Carolyn Jones, Market President & Publisher of the Boston Business Journal, as well as the fellows and network community of The Termeer Foundation, a nonprofit organization working to connect and empower the world of healthcare innovators. The AVEO team is extremely proud of Mr. Bailey’s efforts to inspire tomorrow’s leaders and we salute Belinda Termeer and the entire foundation for its mission of leveraging the collective expertise of industry pioneers to solve complex problems in drug development and accessibility.    #oncology #pharma #biotech #TermeerFoundation #TermeerFellows #leadership #healthcareinnovation #lifesciences #mentorship

Happy National Nurses Week! AVEO Oncology, an LG Chem company, would like to recognize and celebrate all the incredible nurses and the invaluable role they play in our healthcare system. Thank you nurses for all that you do, especially for patients!    #nurses #nationalnursesweek #may2024 #pharma